Lille-Nord de France University (Equipe d'accueil 2694: Epidémiologie et Qualité des Soins), Lille, France.
Crit Rev Oncol Hematol. 2012 Aug;83(2):242-8. doi: 10.1016/j.critrevonc.2011.11.008. Epub 2012 Jan 9.
Life-expectancy superior to 3 months is a key-eligibility criterion for contemporary oncology phase 1 trials. Nevertheless, there is no reliable and consensual guidance for estimating this criterion. We have conducted a systematic review of published studies investigating the risk factor for 90-day mortality and the inherent generated scores. Nine studies have been published on this topic. Only two of these prognostic models have been validated on an independent dataset. Most of the models are based on a very subjective and investigator-dependent parameter: the performance status. The predictive performance of these prognostic models is poorly evaluated.
预期寿命超过 3 个月是当代肿瘤学 1 期试验的关键入选标准。然而，目前还没有可靠且一致的指导意见来估计这一标准。我们对已发表的研究进行了系统回顾，这些研究调查了 90 天死亡率的风险因素和内在产生的评分。有 9 项关于这个主题的研究已经发表。只有其中两个预后模型在独立数据集中得到了验证。这些预后模型中的大多数都是基于一个非常主观和依赖于研究者的参数：表现状态。这些预后模型的预测性能评价不佳。
